Scientific reports · 2025
Spatial heterogeneity and temporal trends of thyroid cancer incidence in Iran from 2014 to 2017.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Soleimani Mohsen, Chiti Hossein
Аннотация
Global thyroid cancer (TC) incidence has risen sharply, yet subnational spatial and temporal patterns, particularly in middle-income contexts like Iran, remain understudied. This study investigates TC's spatial heterogeneity and temporal trends across Iran (2014-2017) to delineate high-risk clusters and guide targeted interventions. Data from the Iranian National Cancer Registry (18,336 cases) were analyzed, with age-standardized rates (ASRs) computed via direct standardization and annual percent changes (APCs) estimated using Poisson regression. Global and Local Moran's I statistics evaluated spatial autocorrelation and clustering by sex, and province. The four-year ASR in Iran was 11.1 per 100,000 (95% CI: 0-28.2), with females at 35.1 (95% CI: 27.4-42.7) versus males at 9.64 (95% CI: 5.9-13.4), reflecting a 3.6-fold sex disparity. Annual ASRs increased from 2.1 to 3.6 per 100,000 (APC: 19.6%), with females (17.6%) exceeding males (11.2%). Grade 9 tumors prevailed (88.2%), most prevalent in females (69.9%) and Yazd (14.5%), rising from 16.8% in 2014 to 28.1% in 2017. Spatial analysis identified high-high clusters in central provinces (e.g., Yazd: 36.6, Esfahan: 17.5 per 100,000) versus low-low clusters in the northeast (e.g., Semnan: 4.8). Peak incidence occurred at 50-54 years (females) and 70-74 years (males). Thyroid Cancer in Iran displays marked sex, geographic, and temporal disparities, propelled by diagnostic enhancements and environmental influences. Standardized registries and selective screening in high-risk zones (e.g., Yazd, Esfahan) are imperative to address this growing burden, aligning with precision public health strategies.